Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification
Open Access
- 16 February 2010
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 127 (11), 2718-2722
- https://doi.org/10.1002/ijc.25247
Abstract
Wildtype (WT) gastrointestinal stromal tumors (GISTs), lacking mutations in KIT or PDGFRA, represent 85% of GISTs in pediatric patients. Treatment options for pediatric WT GIST are limited. Recently, expression profiling of a limited number of pediatric and adult WT GISTs and more in depth study of a single pediatric WT GIST implicated the insulin‐like growth factor 1 receptor (IGF1R) as a potential therapeutic target in pediatric WT GIST. We performed immunoblotting, SNP and FISH studies to determine the extent of expression, biochemical activation and genomic amplification of IGF1R in a larger number of pediatric WT GISTs. Pediatric WT GISTs expressed IGF1R strongly, whereas typical adult KIT mutant GISTs did not. IGF1R gene amplification was not detected in pediatric WT GISTs, and some KIT‐mutant GISTs had IGF1R gene deletion due to monosomy 15. Despite the absence of apparent genomic activation mechanisms accounting for overexpression, clinical study of IGF1R‐directed therapies in pediatric WT GIST is warranted.This publication has 26 references indexed in Scilit:
- Insulin‐like growth factor 1 receptor expression in wild‐type GISTs: A potential novel therapeutic targetInternational Journal of Cancer, 2009
- Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinibPediatric Blood & Cancer, 2009
- Insulin and insulin-like growth factor signalling in neoplasiaNature Reviews Cancer, 2008
- Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupJournal of Clinical Oncology, 2008
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2008
- Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumorsProceedings of the National Academy of Sciences of the United States of America, 2008
- Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patientsAnnals of Oncology, 2008
- Characterizing the cancer genome in lung adenocarcinomaNature, 2007
- Outcome of Metastatic GIST in the Era before Tyrosine Kinase InhibitorsAnnals of Surgical Oncology, 2006
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002